G. Brusselle (Ghent, Belgium), P. Horváth (Budapest, Hungary)
Late Breaking Abstract - Protection by budesonide against clinically important deteriorations (CID) in patients with COPD is dependent on blood eosinophil counts (EOS)
M. Bafadhel (Oxford, United Kingdom), D. Sing (Manchester, United Kingdom), C. Jenkins (Sydney, Australia), S. Peterson (Lund, Sweden), T. Bengtsson (Lund, Sweden), M. Fagerås (Gothenburg, Sweden)
|    |
Blood eosinophilia(BE) and outcomes in patients with acute severe exacerbations of COPD(AECOPD)
A. Soe (Moscow, Russian Federation), M. Kevorkova (Moscow, Russian Federation), G. Nuralieva (Moscow, Russian Federation), A. Belevskiy (Moscow, Russian Federation), S. Avdeev (Moscow, Russian Federation), A. Chuchalin (Moscow, Russian Federation)
|  |
Peripheral eosinophils and mortality in COPD patients over nine years
R. Prudente (Botucatu, Brazil), C. Mesquita (Botucatu, Brazil), R. Ferrari (Botucatu, Brazil), E. Franco (Botucatu, Brazil), S. Tanni (Botucatu, Brazil)
| |
Relationship between blood eosinophil count and bronchial epithelial gene expression in COPD versus Asthma
L. George (Leicester, United Kingdom), J. Riley (Stevenage, United Kingdom), A. Taylor (Stevenage, United Kingdom), S. Bates (Stevenage, United Kingdom), S. Wagers (Basel, Belgium), A. Esteve-Codina (Barcelona, Spain), M. Artigas (Barcelona, United Kingdom), S. Pavlidis (London, United Kingdom), D. Singh (Manchester, United Kingdom), K. Fan-Chung (London, United Kingdom), P. Sterk (Amsterdam, Netherlands), C. Brightling (Leicester, United Kingdom)
| |
Blood eosinophil count predicts severity of respiratory failure, death and future exacerbations in severe life-threatening asthma
A. Yii (Singapore, Singapore), T. Tay (Singapore, Singapore), S. Puah (Singapore, Singapore), H. Lim (Singapore, Singapore), A. Li (Singapore, Singapore), P. Lau (Singapore, Singapore), R. Tan (Singapore, Singapore), L. Neo (Singapore, Singapore), M. Koh (Singapore, Singapore)
| |
Increased IL5, IL8 and eosinophils in induced sputum of asthmatics with accelerated FEV1 decline
M. Marc Malovrh (Golnik, Slovenia), L. Camlek (Golnik, Slovenia), S. Skrgat (Golnik, Slovenia), M. Dezman (Golnik, Slovenia), I. Kern (Golnik, Slovenia), P. Korosec (Golnik, Slovenia)
| |
Persistent blood eosinophilia and COPD exacerbation risk after ICS withdrawal from triple therapy in the SUNSET study
J. R. Hurst (London, United Kingdom), K. Kostikas (Basel, Switzerland), K. R. Chapman (ON, Canada), S. Frent (Timisoara, Romania), M. Larbig (Basel, Switzerland), R. Fogel (NJ, United States of America), T. Guerin (Dublin, Ireland), D. Banerji (NJ, United States of America), F. Patalano (Basel, Switzerland), P. Goyal (Basel, Switzerland), P. Pfister (Basel, Switzerland), J. A. Wedzicha (London, United Kingdom)
| |
Biomarker measurement in asthma patients receiving biologic therapy: a real-world retrospective study
N. Hanania (Houston, United States of America), J. Fang (East Hanover, United States of America), L. Zhou (Morristown, United States of America), B. Ortiz (East Hanover, United States of America), A. Kavati (East Hanover, United States of America), X. Jaumont (Basel, Switzerland), L. Alvares (Basel, Switzerland), H. Cao (East Hanover, United States of America)
| |